Analytical Data
-
基因名
DME
- Application
-
别名
DME；NDUFS2L；NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9. mitochondrial
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8LK56
-
表达区间
1-320aa
-
氨基酸序列
MNSRADPGDRYFRVPLENQTQQEFMGSWIPFTPKKPRSSLMVDERVINQDLNGFPGGEFVDRGFCNTGVDHNGVFDHGAHQGVTNLSMMINSLAGSHAQAWSNSERDLLGRSEVTSPLAPVIRNTTGNVEPVNGNFTSDVGMVNGPFTQSGTSQAGYNEFELDDLLNPDQMPFSFTSLLSGGDSLFKVRQYGPPACNKPLYNLNSPIRREAVGSVCESSFQYVPSTPSLFRTGEKTGFLEQIVTTTGHEIPEPKSDKSMQSIMDSSAVNATEATEQNDGSRQDVLEFDLNKTPQQKPSKRKRKFMPKVVVEGKPKRKPRK
-
分子量
51.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DME, or Dimethylarginine Dimethylaminohydrolase, is an important enzyme involved in the metabolism of nitric oxide and polyamines, which play crucial roles in various physiological processes. The study of recombinant DME protein has gained prominence due to its potential therapeutic applications in cardiovascular diseases, neurodegenerative disorders, and cancer, where dysregulation of nitric oxide pathways is often implicated. Research has focused on elucidating the structure and function of DME, as understanding its catalytic mechanisms could lead to the development of novel inhibitors or activators as drug candidates. The ability to produce recombinant DME in host systems allows for detailed biochemical studies, facilitating insights into enzyme kinetics, interaction with substrates, and the effects of post-translational modifications. Furthermore, advances in protein engineering techniques enable the design of DME variants with enhanced stability and activity, paving the way for innovative therapeutic strategies. Overall, the exploration of DME recombinant protein represents a significant intersection of biochemistry, pharmacology, and translational medicine, with the promise of contributing to more effective treatments for diseases related to nitric oxide dysregulation.
